Pfizer announced on Friday the appointment as Chief Strategy and Innovation Officer of Andrew Baum, previously Head of Pharmaceutical Equity Research at Citi.

Dr. Baum, who holds a medical degree from Oxford University, will take up his new post on June 3, replacing Aamir Malik, recently appointed Chief Commercial Officer for the USA.

Andrew Baum - who has over thirty years' experience - is considered to be the first financial analyst to have highlighted the promising potential of immunotherapies in cancer treatment in a 2011 study.

Prior to joining Citi 13 years ago, he covered pharmaceutical stocks for 14 years, having started his career at the Royal National Orthopaedic Radcliffe Hospital.

In his new role, he will be responsible for evaluating the company's project portfolio and strategic priorities, business development, exploring partnerships with biotechs and the commercial evaluation of drug candidates.

Copyright (c) 2024 CercleFinance.com. All rights reserved.